INTRODUCTION
Bone tissue in adult mammalian animals undergoes continuous remodeling through a tightly controlled balance between bone formation and resorption. This balance is required to maintain physiological bone mass, a critical indicator of bone quality. Osteoblasts, which differentiate from mesenchymal progenitor cells in the bone marrow or periosteum, are responsible for bone formation (reviewed by Harada and Rodan, 2003; Karsenty and Wagner, 2002) , whereas osteoclasts, which are derived from mononucleated hematopoietic cell lineage (Ash et al., 1980) , are responsible for bone resorption. Osteoblasts also regulate bone resorption via inducing osteoclast differentiation by secreting the receptor activator of NFkB ligand (RANKL), monocyte colony stimulating factor (M-CSF), and osteoprotegerin (OPG) (Lacey et al., 1998; Lagasse and Weissman, 1997) . RANKL is essential for osteoclast differentiation. RANKL administration leads to bone resorption (Lacey et al., 1998) , and RANKL-deficient mice are osteopetrotic due to the lack of osteoclast differentiation (Kim et al., 2000; Kong et al., 1999) . OPG is a soluble tumor necrosis factor (TNF) a receptor that inhibits osteoclast differentiation by acting as a decoy receptor for RANKL (Lacey et al., 1998; Simonet et al., 1997; Yasuda et al., 1998) . Abnormal ratios of RANKL and OPG caused by diseases, cancer metastases, and aging lead to either osteoporosis or osteopetrosis (Blair et al., 2006; Hofbauer and Schoppet, 2004; Whyte, 2006) . Therefore, the balance of RANKL and OPG produced in osteoblasts needs to be tightly controlled to maintain bone mass.
Activated canonical Wnt signaling in osteoblasts increases bone mass by inhibiting osteoclast differentiation through upregulating OPG expression (Glass et al., 2005; Holmen et al., 2005) . It is conceivable that other signaling pathways may control bone mass by regulating RANKL expression. A widely studied bone anabolic factor, parathyroid hormone (PTH), acts systemically to regulate bone mass. Parathyroid hormone-related protein (PTHrP) that resembles PTH in its aminoterminal sequence (Karmali et al., 1992; Strewler et al., 1987; Suva et al., 1987; Tsukazaki et al., 1995) and biological activities (Juppner et al., 1991; Kemp et al., 1987; Nissenson et al., 1988 ) is produced locally in articular chondrocytes and osteoblasts. PTH/PTHrP promotes differentiation and survival of osteoblasts (Miao et al., 2005) , which in turn upregulate RANKL expression to induce osteoclast differentiation (Thomas et al., 1999) . Consistent with this notion, PTH induces osteoclast formation from PTHR1-deficient precursors when they are cocultured with PTHR1-expressing bone marrow stromal cells. Therefore, PTH/PTHrP signaling can act in osteoblasts to indirectly induce osteoclast formation through another signaling pathway (Liu et al., 1998) .
Hedgehog (Hh) signaling is required for endochondral bone formation during embryonic development. Mice lacking Indian hedgehog (Ihh) fail to form osteoblasts or activate PTHrP expression in articular chondrocytes (St-Jacques et al., 1999) . Ihh is also expressed in growth plate chondrocytes and osteoblasts postnatally in mice and rats (Jemtland et al., 2003; Murakami et al., 1997; Murakami and Noda, 2000; van der Eerden et al., 2000) . IHH expression is also found in postnatal human growth plates (Kindblom et al., 2002) . Reduced Ihh expression in postnatal chondrocytes leads to reduced trabecular bone (Maeda et al., 2007) . However, it is unclear if the observed defects are caused by reduced osteoblast differentiation from mesenchymal progenitors. It remains to be elucidated whether Hh signaling in differentiated osteoblasts controls postnatal bone formation and remodeling.
Vertebrate Hh signaling is transduced through two multipass transmembrane proteins, Smoothened (Smo) and Patched1 (Ptch1) (reviewed by Huangfu and Anderson, 2006) . In the absence of Hh ligands, Smo signaling activity is inhibited by Ptch1. Such inhibition is relieved when Hh ligands bind Ptch1, allowing Smo to transduce Hh signal to intracellular components. As a major pathway regulating cell proliferation, differentiation, and survival during embryonic morphogenesis, Hh signaling strength is tightly controlled. Ptch1, a negative regulator and a transcriptional target of Hh signaling, acts as a critical ''guardian'' of Hh signaling activities in both embryonic development and adult tissue homeostasis. Ptch1 is a well-established oncosuppressor (Goodrich et al., 1997; Johnson et al., 1996; Oro et al., 1997) . Reduced Ptch1 activity causes the Gorlin Syndrome in humans, which shows skeletal abnormalities and predisposition to several types of tumors (reviewed by Rubin and de Sauvage, 2006) .
Here, we have addressed the function of Hh signaling in osteoblasts during postnatal bone homeostasis by generating mice in which Hh signaling is either activated or blocked genetically in mature osteoblasts. Activation of Hh signaling increased bone formation, but the resulting bone is very fragile and porous due to severe bone resorption. Furthermore, we found that, as in the developing cartilage (St-Jacques et al., 1999; Vortkamp et al., 1996) , upregulated Hh signaling in mature osteoblasts promotes PTHrP expression. PTHrP signals via PKA and CREB to upregulate RANKL expression. Conversely, loss of Hh signaling resulted in increased bone mass and much reduced bone loss in older mice. Our results have uncovered a novel role of Hh signaling, which is to promote bone resorption and identified upregulation of Hh signaling in mature osteoblasts as a key event in causing osteoporosis.
RESULTS

Hh Signaling Progressively Decreases as Osteoblasts Mature
To determine Hh signaling activity in postnatal bone, we tested if Ptch1, a transcriptional target of Hh signaling, was expressed in the postnatal skeletal system using a LacZ knockin null allele of Ptch1, which was derived from a floxed allele of Ptch1 (Mak et al., 2006) . After Cre-mediated recombination, the LacZ gene is brought under the control of the Ptch1 regulatory elements. We assessed Hh signaling activity by X-gal staining of these Ptch1 +/À mice at postnatal day 5 (P5) and focused our analysis on the perichondrium and bone in the forelimbs. Strong staining was found in the perichondrium in the Ptch1 +/À mice ( Figures   1A and 1C ) and progressively reduced as the osteoblasts became more mature in the cortical and trabecular bone ( Figures  1C and 1E ). There was no detectable staining in the osteocytes ( Figure 1E ). In addition, X-gal staining was detected in the calvarial osteoblasts of both P5 and one-year-old mice (see Figure S1 in the Supplemental Data available with this article online). Again, as osteoblasts matured and grew further away from the suture, X-gal staining was reduced progressively (Figures S1A and S1B). These results suggest that Hh signaling may need to be properly downregulated in mature osteoblasts of the postnatal bone.
Activation of Hh Signaling in Mature Osteoblasts
Leads to Severe Osteopenia Progressively weakened Hh signaling in mature osteoblasts suggests that sustained high levels of Hh signaling in these cells is likely to be deleterious to the adult bone. To test this, we activated Hh signaling by crossing the mice carrying a floxed allele of Ptch1 (Mak et al., 2006) with the human Osteocalcin-Cre (HOC-Cre) mice that express the Cre recombinase in mature osteoblasts and osteocytes (Zhang et al., 2002 and Figures 1B, 1D, and 1F) to obtain the Ptch1 c/À ;HOC-Cre mice. These mice appeared normal at birth and were born at the expected Mendelian ratio. However, a significant growth retardation was observed ( Figure S2A ). The skull was bigger and dome shaped, and the eyes were further apart from each other in the mutant (Figure 2A ). These phenotypes resemble the skull and facial features (frontal, biparetial, or temporal bossing; large calvaria; and hypertelorism) of Gorlin Syndrome patients, which have reduced PTCH1 activity (Balsa et al., 1985; Lambrecht and Kreusch, 1997; Lo Muzio et al., 1999) . Many of the Ptch1 c/À ;HOC-Cre mice had difficulties in walking and breathing, likely due to the smaller rib cages and lower bone density ( Figure S2B ). The long bones were more fragile in the Ptch1 c/À ;HOC-Cre mice as fractures were frequently observed in at least one limb of the mutant mouse ( Figure S2B ). In contrast to the reduced bone density, significant bone overgrowth in rib, humerus, and femur of the Ptch1 c/À
;HOC-Cre mice was revealed by computed tomography (CT) scan ( Figure S2C ). In addition, the serum alkaline phosphatase activity, a bone formation marker, was also higher in the mutant than the wild-type ( Figure S2E ). These observations prompted us to examine the bone quality by microcomputed tomography (mCT) analysis. The cortical and trabecular bone mass were greatly reduced in most areas of the Ptch1 c/À ; HOC-Cre mice, and the trabecular number was significantly reduced ( Figures 2B, 2C , and 2G) with an increased ratio of bone surface to volume ( Figure 2G ). These results indicate that in the Ptch1 c/À ;HOC-Cre mice, bone formation is increased, but the formed bone is more porous due to accelerated bone turnover. Reduced bone mass was also observed in the membranous bone of the skull ( Figure S2D ). Thus, in contrast to the limited role of Ihh in endochondral bone formation in embryonic development (St-Jacques et al., 1999) , activation of Hh signaling in the mature osteoblasts resulted in marked reduction in bone mass regardless of the ossification mechanism.
Hh Signaling Promotes Both Bone Formation and Resorption
To investigate bone formation and resorption of the Ptch1 c/À ; HOC-Cre mice in more detail, we sectioned the tibia of P52 mice and performed Van Gieson staining by which collagen in the bone matrix is stained red and smooth muscle cells are stained yellow ( Figure 2D ). In the Ptch1 c/À ;HOC-Cre limb, the primary and secondary spongiosa were present, indicating that upregulation of Hh signaling in mature osteoblasts does not affect chondrocyte hypertrophy and maturation (Figure S3) . However, both the cortical and trabecular bones were much thinner, and the primary spongiosa region was expanded by massive bone marrow invasion in the mutant ( Figure 2D ). In some areas of the bone, there was obviously more bone growth, but the resulting bone was more porous ( Figure 2D ). These results suggest that the normal balance of os- ; HOC-Cre mutant mice, the number of osteoblasts was increased (Figures 2E and 2G) . However, the increase in the number of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts was more significant (Figures 2F and 2G) . These observations suggest that enhanced bone resorption is dominant over increased bone formation when Hh signaling was cell-autonomously upregulated in mature osteoblasts.
To test whether increased bone formation was caused by altered osteoblast proliferation and/or survival, we examined the expression of proliferating cell nuclear antigen (PCNA) (Figures 3A and 3B) and performed TUNEL assays ( Figures 3D  and 3E ). In the Ptch1 c/À ;HOC-Cre bone section, there were more PCNA-positive osteoblasts. Furthermore, we assessed bone formation rate by in vivo calcein double labeling ( Figure 3C ).
Ptch1 c/À
;HOC-Cre mice showed increased calcein incorporation without consistent double labeling, reflecting the increased number and disorganization of the osteoblasts during the rapid osteogenesis that resulted in woven bone ( Figures 3C and 2E ). In addition, TUNEL assay showed fewer apoptotic osteoblasts in the Ptch1 c/À ;HOC-Cre mice ( Figures 3D and 3E ).
These results indicate that upregulated Hh signaling in mature osteoblasts leads to accelerated bone formation by promoting cell proliferation and survival. ;HOC-Cre mice can also be caused by enhanced osteoblast differentiation due to upregulated Hh signaling, we examined gene expression associated with osteoblast differentiation in the adult bone by quantitative RT-PCR (QRT-PCR) ( Figure 4A ). As expected, there was no change in the initial osteoblast differentiation indicated by Runx2 expression. However, further differentiation of (D-F) QRT-PCR results using the RNA isolated from the calvarial cultures as described in (B) and (C). All data are means ±SD from triplicate samples.
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Hh Controls Bone Homeostasis via PTHrP and RANKL committed osteoblasts was enhanced as expression of Osterix (Osx), Osteocalcin (Oc), a marker for mature osteoblasts, and dentin matrix protein 1 (Dmp1), an early osteocyte marker, were increased. In addition, expression of Tcf1, a transcription factor that mediates Wnt/b-catenin signaling, was upregulated (Galceran et al., 1999; Glass et al., 2005) ;HOC-Cre mice ( Figure 5C ). The expression of PTH, which signals through the same receptor as PTHrP, was not upregulated. Cre-adenovirus-infected Ptch1 c/c calvarial cells also showed an increase in the expression of RANKL ( Figure 5D ) and PTHrP ( Figure 5E ). Interestingly, such increase happened earlier than that of the osteoblast markers we examined ( Figures  4D-4F ), suggesting that regulation of RANKL and PTHrP expression by Hh signaling does not depend on the status of osteoblast differentiation. There was no significant difference in OPG ( Figure 5F ) and PTH ( Figure 5G) ;HOC-Cre mice were isolated and cultured in vitro under osteogenic conditions. Consistent with previous findings (Thomas et al., 1999) , PTHrP-treated wild-type cells showed upregulated RANKL expression and downregulated OPG expression ( Figure 5H ). Such alteration in gene expression was not inhibited by a Hh-signaling inhibitor Cyclopamine (Cooper et al., 1998;  Figure 5H ;HOC-Cre osteoblasts induced more osteoclast formation, such increase was abolished by PTHrP-neutralizing antibodies ( Figures 5I and 5J ). These results demonstrate that PTHrP is both necessary and sufficient to mediate the effect of Hh signaling in promoting RANKL expression and osteoclast differentiation.
PTHrP Regulates RANKL Expression through PKA and CREB To understand the underlying molecular mechanism whereby PTHrP signaling controls RANKL expression in osteoblasts, we searched the transcription factors that have been reported to regulate RANKL expression directly. Among these, CREB and ATF4 were strong candidates. CREB and ATF4 are members of the CREB family of basic leucine zipper transcription factors, which bind the cyclic AMP-responsive element (CRE) as homodimers or heterodimers and activate transcription upon phosphorylation by PKA (Shaywitz and Greenberg, 1999 osteoblasts by directly binding a CRE site in the RANKL promoter (Elefteriou et al., 2005; Ishida et al., 2002) . In addition, the common receptor of PTH and PTHrP activates adenylyl cyclase (AC)/protein kinase A (PKA) (Bringhurst et al., 1993; Fujimori et al., 1992 ;HOC-Cre osteoblasts as compared to the wild-type control ( Figure 6A ). CREB transcription activity was also upregulated in the Ptch1 c/À ;HOCCre osteoblasts ( Figure 6B ). In addition, treating primary calvarial osteoblasts with PTHrP leads to fast (within 10 min) and robust CREB phosphorylation ( Figure 6C ). The level of phosphorylation was similar to that caused by Forskolin (a cAMP-elevating agent) treatment or expression of an activated form of PKA. Furthermore, inhibition of PKA by H89 abolished PTHrP-induced CREB phosphorylation ( Figure 6C ). To test whether PKA and CREB mediate the activity of PTHrP in regulating RANKL expression, we treated primary calvarial osteoblasts with PTHrP in the presence H89 or an adenovirus that carries a dominant-negative CREB (aCREB-Adenovirus) that can block the transcriptional activity of all CREB family members (Chen et al., 2005) . RANKL upregulation by PTHrP or Shh or in the Ptch1 c/À ;HOC-Cre osteoblasts was inhibited by H89 and aCREB-Adenovirus infection ( Figures 6D and 6E ). To further test whether CREB directly regulates RANKL expression in osteoblasts, we examined the regulation of a 1 kb RANKL promoter that contains CREB-binding sites (Ishida et al., 2002) by the PTHrP-PKA-CREB pathway. This RANKL promoter activity was activated by PTHrP but inhibited by H89 or aCREB-Adenovirus infection even in the presence of PTHrP ( Figure 6F ). To test whether pCREB binds to this RANKL promoter directly, we performed chromatin immunoprecitiation (CHIP) assay. Consistent with the previous observation which showed by the eletrophoretic mobility shift assay (EMSA) that CREB mainly binds to the À945 CRE site in the RANKL promoter upon TGFb treatment (Ishida et al., 2002) , more DNA of the À945 region of the RANKL promoter was immunopecipitated by antibodies against CREB or pCREB in the Ptch1 c/À ;HOC-Cre osteoblasts or upon PTHrP treatment (Figures 6G and 6H ). Taken together, PTHrP signaling regulates RANKL expression through activating PKA and its target transcription factor CREB that directly binds to the RANKL promoter.
Loss of Hh Signaling in Mature Osteoblasts Results in High Bone Mass
That cell-autonomous upregulation of Hh signaling in mature osteoblasts promoted bone resorption raised the possibility that active Hh signaling in mature osteoblasts contributed to bone loss in aged mice. To test this, Hh signaling in the bone of 3-, 6-, and 12-month-old mice was assessed by the expression of Hh-signaling target genes Ptch1, Gli1, and Hip1 (Bai et al., 2002; Chuang and McMahon, 1999; Goodrich et al., 1996) . Hh signaling was lower in the bone of 3-month-old mice ( Figure 7A ). Consistent with this, PTHrP and RANKL expression were slightly upregulated in older mice ( Figure 7A) . As a result, osteoblasts from older mice induced more osteoclast formation when cocultured with the same osteoclast precursors (Figure S6) . We then investigated whether Hh signaling is required in osteoblasts to control osteoclast differentiation and whether inhibition of Hh signaling in osteoblasts would protect bone loss observed in aged mice. Smo, which is required for transducing Hh signaling, was inactivated in mature osteoblasts in the Smo c/c ;HOC-Cre mice. These mice were viable and morphologically normal throughout their lives. At 2 months of age, no significant difference in bone morphology and mass was observed in the mutant mice ( Figure S7 ). About 40% of the conditional allele had been converted to a null allele and Hh signaling was significantly reduced in the 1-year-old Smo c/c ;HOC-Cre mice ( Figure S4E ; Figure 7H ). In these 1-year-old mutant mice, trabecular bone mass was increased compared to the wild-type control ( Figures 7C-7E ). Cortical bone mass in the mutant was also slightly increased ( Figure 7E ). Importantly, the 1-year-old wild-type control mice showed significant trabecular bone loss compared to the 2-month-old ones (compare Figures 7C and  7D Together, our data demonstrate that Hh signaling in mature osteoblasts plays a critical role in controlling postnatal bone turnover and that its signaling strength is key to age-related bone loss by regulating the balance of bone formation and resorption.
DISCUSSION
Hh signaling acts at multiple critical steps in controlling chondrocyte and osteoblast proliferation and differentiation during endochondral bone development. Here, we report that Hh signaling in mature osteoblasts in adult mice promotes bone (D-G) Gene expression was examined by QRT-PCR using the RNA isolated from the calvarial osteoblast cultures described in Figure 4 . 
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Hh Controls Bone Homeostasis via PTHrP and RANKL formation by enhancing osteoblast proliferation, differentiation, and survival. More importantly, Hh signaling also acts in osteoblasts to regulate osteoclast differentiation by controlling the expression of PTHrP, which in turn regulates RANKL expression via PKA and its target transcription factor CREB ( Figure 7J ).
Our results indicate that in mature osteoblasts, Hh signaling regulates a delicate balance between bone growth and resorption via cell-autonomous and non-cell-autonomous mechanisms, respectively.
Stage and Cell Context-Dependent Roles of Hh Signaling in Bone Formation and Homeostasis
The ligand that activates Hh signaling in the skeletal system is Ihh. Ihh in the newly formed cartilage is required for osteoblast differentiation by controlling Runx2 expression in the perichondrium. Runx2 then controls the expression of Osx, another transcription factor also required for osteoblast lineage commitment (Nakashima et al., 2002) . Hh signaling is not required in Osx + osteoblasts for further osteoblast maturation in mouse embryos (Rodda and McMahon, 2006) . It is not clear whether Hh signaling is required in the Osx + osteoblasts during postnatal bone homeostasis. By inactivating Hh signaling in mature osteoblasts after Osx expression, we found in this study that Hh signaling is required to control both postnatal bone formation and resorption.
In the growth plate, Ihh expression is confined to prehypertrophic chondrocytes. A major role of Ihh at this stage is to control the pace of chondrocyte hypertrophy by activating the expression of PTHrP, which inhibits chondrocyte hypertrophy (Kronenberg, 2003) . Our data show that Hh signaling in mature osteoblasts in adult mice also acts by regulating PTHrP expression, likely through Gli2 and Gli3 ( Figure S8 ). Consistent with this, both PTHrP and upregulated Hh signaling in committed osteoblast precursors promoted their differentiation and reduced their apoptosis (Miao et al., 2005;  Figure 3 ). As shown in Ohba et al. 2008 (in this issue of Developmental Cell), Hh signaling may also regulate osteoblast differentiation directly by inhibiting the production of Gli3 repressor, which inhibits Runx2 transcription activity. More importantly, PTHrP mediates the non-cell-autonomous role of Hh signaling in inducing osteoclast differentiation through regulating RANKL expression. This is consistent with the previous finding that sustained PTHrP expression leads to increased bone resorption (Ma et al., 2001) . Our data further indicate that PTHrP regulates RANKL expression by activating PKA and its target transcription factor CREB. We should point out here that other CREB family members including ATF4 may also act downstream of PKA to regulate RANKL expression.
Since PTHrP stimulates both bone formation and resorption in early differentiated osteoblasts, PTHrP expression must be tightly regulated both temporally and spatially in order to control bone formation and avoid increased osteoclast differentiation. Our studies indicate that Hh signaling represents a critical regulatory mechanism for the temporal and spatial control of PTHrP expression ( Figure 7J ). Ihh expression and activity are detected in the growth plate chondrocytes and early differentiated osteoblasts. Hh signaling decreases progressively as the osteoblasts mature and are further away from the growth plates (Figure 1 ). This distribution of Hh signaling activity correlates very well with the expression pattern of PTHrP in osteoblasts and the ability of osteoblasts to induce osteoclast differentiation. Osteogenic progenitors produce PTHrP at early differentiation stages, and PTHrP levels decrease with further osteoblast maturation (Miao et al., 2005; Suda et al., 1996) . In addition, Hedgehog ligands promote both PTHrP mRNA expression and PTHrP secretion in primary osteoblast cultures (Jemtland et al., 2003) . Therefore, our work identifies PTHrP as one of the critical downstream targets of Hh signaling in postnatal bone homeostasis. Our data also indicate that Hh signaling needs to be kept at a low level in mature osteoblasts to ensure low PTHrP expression and prevent excessive osteoclast formation.
The roles of Hh signaling in bone homeostasis obviously depend on the signaling strength and the cell context. Figure S9A ). Bmp signaling promotes bone formation and stimulates osteoclast differentiation through a RANKL-independent mechanism (Okamoto et al., 2006) . Bmps may directly signal to osteoclast precursors to promote osteoclast differentiation ( Figure S9D ; Okamoto et al., 2006; Kaneko et al., 2000) . In the primary calvarial osteoblasts, we found that Bmps and PTHrP did not regulate the expression of each other (data not shown). In addition, inhibition of osteoclast differentiation by Noggin, a secreted Bmp antagonist, could be 
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Hh Controls Bone Homeostasis via PTHrP and RANKL rescued by PTHrP ( Figure S9B and S9C), suggesting that PTHrP and Bmp may act in parallel to regulate osteoblast and osteoclast differentiation downstream of Hh signaling. It will be interesting to further investigate the molecular mechanism of Bmp signaling in controlling osteoclast differentiation.
Both Hh and Wnt/b-catenin signaling pathways are required in osteoblasts to regulate osteoclast differentiation. Hh signaling has been placed upstream of Wnt/b-catenin signaling during early osteoblast differentiation in skeletal development (Hu et al., 2005; Mak et al., 2006; Rodda and McMahon, 2006) . In the differentiated osteoblasts, Hh signaling activity appears to be mediated by at least two downstream signaling pathways: Wnt/b-catenin and PTHrP. While both signaling pathways act to promote bone formation, they have opposite roles in osteoclast differentiation. PTHrP signaling promotes osteoclast differentiation by upregulating RANKL expression and inhibiting OPG expression. But Wnt/b-catenin signaling inhibits osteoclast differentiation primarily by upregulating OPG expression. As Wnt/b-catenin and PTHrP cancel each other's effect in regulating OPG expression, Hh signaling controls osteoclast differentiation mainly through RANKL.
Hh Signaling as a Therapeutic Target for Osteoporosis
Hh signaling promotes osteoblast differentiation from mesenchymal progenitors and osteoblast maturation. Therefore, augmenting Hh signaling could be beneficial in treating osteoporosis. However, upregulated Hh signaling will lead to increased tumor formation as shown in the Gorlin Syndrome patients. In addition, one must carefully evaluate the differential impacts of timing, cell types, and strength of Hh signaling on bone formation versus resorption. Our results indicate that sustained high levels of Hh signaling in mature osteoblasts will reduce bone quality by making the bone more porous due to increased osteoclast formation. Growth plates exist in the adult mouse bone for long time, whereas in humans, growth plates close at puberty. As growth plate chondrocytes are the major source of Ihh, the effect of Hh signaling in adult human bone homeostasis may not be as strong as in mice. However, Ihh expression is detected in primary osteoblasts which also respond to Hh signaling. Thus, genetic mutations that cause Hh signaling activation preferentially in mature osteoblasts in humans are likely to result in early onset of osteoporosis. It may be therefore more efficient to increase bone mass and reduce the risk of tumor formation by alternating between enhancing and inhibiting Hh signaling periodically to generate more osteoblasts and pulses of PTHrP expression that have been shown to favor bone formation versus bone resorption (Jilka, 2007) .
EXPERIMENTAL PROCEDURES Histological Analysis
Whole-mount X-gal staining was performed as previously described (Topol et al., 2003) . Primary antibodies used in immunohistochemistry include anti-PCNA mouse monoclonal IgG (Santa Cruz) at 1:50, anti-Phosphohistone-3 rabbit polyclonal IgG (Cell Signaling) at 1:100, and anti-phospho-CREB (Ser 133) rabbit polyclonal IgG (Upstate) at 1:100. The signal was detected using FITC-conjugated secondary antibodies (Molecular Probes) or ABC kits (Vector Laboratories). Apoptosis was detected as described (Barrow et al., 2003) . TRAP staining was detected according to manufacturer's protocol (Sigma). Calcein double labeling was performed as described (Sontag, 1980) except that calcein was injected at day 10 and 2 before the mice were sacrificed. Static and dynamic histomorphometric analyses were performed according to standard protocols (Parfitt et al., 1987) .
Calvarial Cell Culture
Calvariae were dissected from P1 to P3 newborn pups. Soft tissue was removed and the calvariae were washed in PBS and subjected to five sequential digestions by 0.5% collagenase (Roche) in a-MEM medium at 37 C for 25 min each. The cells from the last four digestions were collected and expanded for subsequent cultures. 2.5 3 10 5 cells were seeded per well in 12-well plates and switched into osteogenic medium with ascorbic acid and glycerophosphate after reaching superconfluence.
Quantitative RT-PCR Quantitative PCR was performed to measure the relative mRNA levels using Platinum SYBR Green kit (Invitrogen). Samples were normalized with GAPDH and actin expression.
Coculture Experiments
Primary osteoblasts from calvariae were seeded at 2 3 10 5 per well in 24 wells and cultured in osteogenic medium as described above. Hematopoietic mononucleated precursors of osteoclasts were isolated from bone marrow and FACS sorted for TER119 À CD4 À CD8 À Mac-1 + CD45 + cells. 0.8 3 10 6 sorted cells were seeded per well on top of the calvarial osteoblasts for 10 days. The medium was supplemented with M-CSF (10 ng/ml) and 1, 25 dihydroxyvitamin D3 (10 À8 M). Osteoclasts were identified by TRAP staining and counted in triplicates.
Microcomputed Tomography Analysis
The femurs and calvariae were scanned and reconstructed with 8 mm isotropic voxels on a microcomputed tomography analysis (mCT) system (eXplore MS, GE Medical Systems, London, Ontario, Canada). A bone standard (SB3, Gammex RMI, Middleton, WI) was scanned with the mCT and used for the calibration of bone-mass measurements. The reconstructed 3D imagines of distal femurs and calvariae were analyzed using Microviewer (GE Medical Systems, London, Ontario, Canada). A fixed threshold was used to separate the bone and marrow phase. The trabecular BMD and trabecular bone volume per tissue volume (BV/TV) in the distal femur were measured in a rectangular cylinder (1.3 mm 3 0.6 mm 3 1.9 mm) within the metaphysis.
(E) Histomorphometric analysis of bone parameters in the femur of 1-year-old mice. Bone mass and bone volume were significantly reduced in the wild-type mouse. Three individual samples of each genotype were analyzed. 
Dual Luciferase Assay
Primary osteoblasts were transfected with Luc reporters by nucleofection (Amaxa). Procedures were followed as described in the manufacturer's protocol. After nucleofection, cells were recovered for 4-5 hr and then infected by the aCREB-Adenovirus for 24 hr, serum starved overnight, and treated with PTHrP (3 mg/ml) and/or H89 (30 mM) for 4 hr. Cells were subjected to luciferase activity measurement as described in Dual luciferase reporter assay kit (Promega).
Western Blot Analysis
Primary osteoblasts were transfected with a constitutive active form of PKA. Transfected and untransfected cells were serum starved overnight. Untransfected cells were treated with PTHrP, H89, and Forskolin (10 mM) for 10 min, 1, 2, and 5 hr. H89 was added to the medium 30 min before adding PTHrP or Forskolin. Cell lysates were analyzed by western blot as described (Topol et al., 2003) . Primary antibodies used include: rabbit anti-phospho-CREB (Ser133) and rabbit anti-CREB (Upstate).
Chromatin Immunoprecipitation
Primary osteoblasts (1310 6 cells) were fixed with 1% formaldehyde directly in culture medium at 37 C for 10 min. Cells were sonicated for four cycles of 10 s each. Immunoprecipitation was performed using the Chromatin immunoprecipitation (CHIP) assay kit (Upstate) with rabbit anti-CREB antibody (Upstate) and rabbit anti-phospho-CREB antibody (Upstate).
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